National Asset Management, Inc. Bio N Tech Se Transaction History

National Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	BUY	$102.58 - $129.66 $224,752 - $284,085	2,191 New	2,191 $236,000
Q3 2022 Nov 14, 2022	BUY	$127.65 - $183.11 $51,060 - $73,244	400 Added 15.31%	3,013 $407,000
Q2 2022 Aug 12, 2022	BUY	$123.25 - $186.24 $322,052 - $486,645	2,613 New	2,613 $390,000
Q1 2022 May 02, 2022	SELL	$126.25 - $231.85 $313,857 - $576,379	-2,486 Closed	0 $0
Q4 2021 Jan 28, 2022	SELL	$216.64 - $362.52 $263,217 - $440,461	-1,215 Reduced 32.83%	2,486 $641,000
Q3 2021 Nov 16, 2021	SELL	$205.93 - $447.23 $315,072 - $684,261	-1,530 Reduced 29.25%	3,701 $1.01 Million
Q2 2021 Aug 10, 2021	SELL	$113.32 - $241.49 $382,455 - $815,028	-3,375 Reduced 39.22%	5,231 $1.17 Million
Q1 2021 May 13, 2021	SELL	$85.73 - $119.5 $131,509 - $183,313	-1,534 Reduced 15.13%	8,606 $940,000
Q4 2020 Feb 04, 2021	BUY	$72.71 - $129.54 $391,252 - $697,054	5,381 Added 113.07%	10,140 $827,000
Q3 2020 Nov 09, 2020	BUY	$57.81 - $104.17 $275,117 - $495,745	4,759 New	4,759 $330,000

360

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $30B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.